Загрузка...
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic and pharmacokinetic/pharmacodynamic relationships were evaluated. Using nonlinear mi...
Сохранить в:
| Главные авторы: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4175417/ https://ncbi.nlm.nih.gov/pubmed/23553560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.73 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|